Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study

被引：0
|
作者：
Ueshima, Kazuomi
Kudo, Masatoshi
Tsuchiya, Kaoru
Kato, Naoya
Yamashita, Tatsuya
Shimose, Shigeo
Numata, Kazushi
Kodama, Yuzo
Tanaka, Yasuhito
Kuroda, Hidekatsu
Itoh, Shinji
Aikata, Hiroshi
Hiraoka, Atsushi
Moriguchi, Michihisa
Wada, Yoshiyuki
Nakao, Kazuhiko
Tateishi, Ryosuke
Ogasawara, Sadahisa
Yamamoto, Kouji
Ikeda, Masafumi
机构：
[1] Kindai Univ, Fac Med, Osaka, Osaka, Japan
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Musashino, Japan
[4] Chiba Univ, Grad Sch Med, Dept Gastroenterol, Chuo Ku, Chiba, Japan
[5] Kanazawa Univ Hosp, Kanazawa, Japan
[6] Kurume Univ Hosp, Kurume, Japan
[7] Yokohama City Univ, Med Ctr, Yokohama, Japan
[8] Kobe Univ, Div Gastroenterol, Dept Internal Med, Grad Sch Med, Kobe, Japan
[9] Kumamoto Univ, Dept Gastroenterol & Hepatol, Fac Life Sci, Kumamoto, Japan
[10] Iwate Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Yahaba, Japan
[11] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[12] Hiroshima Prefectural Hosp, Dept Gastroenterol, Hiroshima, Japan
[13] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan
[14] Kyoto Prefectural Univ Med, Kyoto, Japan
[15] Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan
[16] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki, Japan
[17] Univ Tokyo Hosp, Bunkyo Ku, Tokyo, Japan
[18] Chiba Univ, Grad Sch Med, Chiba, Japan
[19] Yokohama City Univ, Dept Biostat, Sch Med, Yokohama, Japan
[20] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4125
引用
收藏
页数：1
相关论文
共 46 条
  • [31] Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
    Huang, Zhenkun
    Chen, Tiejun
    Li, Wenbin
    He, Wei
    Liu, Shaoru
    Wu, Zongfeng
    Li, Binkui
    Yuan, Yunfei
    Qiu, Jiliang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 139
  • [32] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Shao, Yu-Yun
    Finn, Richard S.
    Galle, Peter R.
    Ducreux, Michel
    Cheng, Ann-Lii
    Yamashita, Tatsuya
    Koga, Hironori
    Take, Ryosuke
    Yamada, Kyoko
    Asakawa, Takashi
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (04) : 401 - 412
  • [33] Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study
    Chen, Shiguang
    Zhang, Kongzhi
    Liu, Weifu
    Yu, Wenchang
    EUROPEAN JOURNAL OF CANCER, 2020, 134 : 90 - 98
  • [34] IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study
    Kudo, Masatoshi
    Finn, Richard S. S.
    Galle, Peter R. R.
    Zhu, Andrew X. X.
    Ducreux, Michel
    Cheng, Ann-Lii
    Ikeda, Masafumi
    Tsuchiya, Kaoru
    Aoki, Ken-ichi
    Jia, Jing
    Lencioni, Riccardo
    LIVER CANCER, 2023, 12 (03) : 238 - 250
  • [35] Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study
    Chen, Song
    Guo, Wenbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study
    Oshita, Ko
    Kobayashi, Tsuyoshi
    Namba, Yosuke
    Fukuhara, Sotaro
    Matsubara, Keiso
    Takei, Daisuke
    Nakano, Ryosuke
    Okamoto, Wataru
    Sakai, Hiroshi
    Tanimine, Naoki
    Nakahara, Takashi
    Kuroda, Shintaro
    Tahara, Hiroyuki
    Ohira, Masahiro
    Kawaoka, Tomokazu
    Ide, Kentaro
    Imamura, Michio
    Aikata, Hiroshi
    Ohdan, Hideki
    BMJ OPEN, 2023, 13 (10):
  • [37] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kakizaki, Satoru
    LIVER CANCER, 2024, 13 (06) : 669 - 670
  • [38] Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
    Kudo, Masatoshi
    Finn, Richard S.
    Cheng, Ann-Lii
    Zhu, Andrew X.
    Ducreux, Michel
    Galle, Peter R.
    Sakamoto, Naoya
    Kato, Naoya
    Nakano, Michitaka
    Jia, Jing
    Vogel, Arndt
    LIVER CANCER, 2023, 12 (05) : 479 - 493
  • [39] Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Yamashita, Tatsuya
    Koga, Hironori
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (06) : 671 - 673
  • [40] A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage
    Zhou, Jian
    Fan, Jia
    Gu, Fang-Ming
    Li, Tao
    Bai, Dou-Sheng
    Sun, Hui-Chuan
    Wang, Zheng
    Qiu, Shuang-Jian
    Ye, Qing-Hai
    Shi, Ying-Hong
    Gao, Qiang
    Wang, Xiao-Ying
    Yang, Xin-Rong
    Shi, Guo-Ming
    Peng, Yuan-Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345